Form 4: Contineum Therapeutics Executive Stephen L. Huhn Exercises Stock Options
SEC Form 4 Filing
Stephen L. Huhn, CMO & Sr VP, Clinical Development at Contineum Therapeutics, exercised stock options to acquire 12,800 shares of Class A Common Stock at $1.01 per share.
Summary
- On August 13, 2024, Stephen L. Huhn, CMO & Sr VP, Clinical Development at Contineum Therapeutics, exercised stock options.
- This transaction involved the cash exercise of stock options to acquire 12,800 shares of Class A Common Stock at a price of $1.01 per share.
- Following the transaction, Mr. Huhn directly owns 12,800 shares of Class A Common Stock.
- Mr. Huhn also directly owns 161,394 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option exercises, which is neutral in sentiment.
Industry Context
This is a routine disclosure of stock option exercises by a company executive, which is a common practice in publicly traded companies to incentivize and reward employees.
Stakeholder Impact
- The exercise of stock options could have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/24/2030 | Expiration date of stock options. |
| 08/13/2024 | Date of stock option exercise. |
| 08/14/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.